Challenges of Health Economic Evaluations Alongside Innovative Clinical Trial Designs in Precision Oncology – Results of a Literature Review

Author(s)

Störzel M, Molnar A, Muchadeyi M, Schlander M
German Cancer Research Center (DKFZ), Heidelberg, BW, Germany

OBJECTIVES: Research advancements in cancer therapies are rapidly moving towards precision medicine. For health economists new clinical trial designs bring various challenges while conducting economic analyses. This comprehensive literature review aims to synthesize published evidence on these challenges and to provide an incentive to discover potential solutions.

METHODS: The literature search was conducted in PubMed on September 9, 2021 using a search string constructed from terms describing relevant clinical trial designs, precision medicine, and health economic evaluations, restricted to challenges or issues. All English language studies that addressed methodological considerations of health economic evaluations on innovative clinical trials in the field of precision medicine were included. References of relevant systematic reviews were searched to identify further records.

RESULTS: The database search yielded 241 hits and additional 5 studies were found through reference screening. Ten studies met inclusion criteria for the qualitative synthesis. Methodological challenges were extracted and categorized under choice of perspective, time horizon, discounting, comparator selection, measurement of costs and health outcomes, and handling uncertainties and data gaps. Several issues arise from small study populations and short clinical trial time horizons, which hinder the assessment of clinical and cost-effectiveness of innovative cancer treatments. Challenges well-known to traditional cost-effectiveness analyses are as well found to be amplified in the field of precision medicine.

CONCLUSIONS: Precision medicine offers significant health benefits through therapeutic approaches tailored to the individual patients. Yet, to gain market access and reimbursement, these investigational treatments need to be evaluated by their clinical effectiveness and cost-effectiveness. Our literature review identified numerous challenges; however, the list of potential solutions is rather limited. To address this complex topic, further research will be needed to explore how to conduct health economic evaluations alongside clinical trials in precision oncology.

Conference/Value in Health Info

2022-11, ISPOR Europe 2022, Vienna, Austria

Value in Health, Volume 25, Issue 12S (December 2022)

Code

EE499

Topic

Study Approaches

Topic Subcategory

Clinical Trials, Literature Review & Synthesis

Disease

SDC: Oncology, STA: Personalized & Precision Medicine

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×